Company news: testosterone treatment boom, AstraZeneca

Share this article:

Drug makers have upped their promotional spending for testosterone therapy by more than 170% over the past three years, to more than $14 million last year, and prescriptions have jumped almost 90% over the past five, reported the Washington Post. The news outlet noted that the surge in the male anti-aging prescription market culminated in $1.9 billion in global sales last year, but that government researchers aren't sold on the treatments. “Evidence of the benefits of testosterone is mixed, and the potential health risks are serious,” reported the Post, which noted that the National Institute on Aging has an 800-man trial underway to test purported benefits of testosterone, such as sexual function, energy and memory, among men 65 and older. Results are expected in 2014.


AstraZeneca has removed its Phase I obesity treatment, AZD2820, from its slate of pipeline contenders, reported Dow Jones. The wire service said a severe reaction was behind the drug maker's decision to pull support from the AZN-Palatin collaboration, but noted that the patient's illness had not been directly linked to the experimental treatment.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.